1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Nivolumab plusCabozantinib versusSunitinib forAdvanced Renal-CellCarcinoma Toni K. ChoueiriThomas PowlesMauricio Burotto2021 год

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.
Год издания: 2021
Авторы: Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C. Goh, Carlos H. Barrios, Martin Eduardo Richardet, Camillo Porta, Rubén Dario Kowalyszyn, Juan P. Feregrino, Jakub Żołnierek, David Pook, Elizabeth R. Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew Maurer, Burçin Şimşek, Flavia Ejzykowicz, Gisela Schwab, Andrea B. Apolo, Robert J. Motzer
Издательство: Massachusetts Medical Society
Источник: New England Journal of Medicine
Ключевые слова: Renal cell carcinoma treatment, Renal and related cancers, Pancreatic and Hepatic Oncology Research
Другие ссылки: New England Journal of Medicine (PDF)
New England Journal of Medicine (HTML)
Digital Commons@Becker (Washington University School of Medicine) (PDF)
Digital Commons@Becker (Washington University School of Medicine) (HTML)
PubMed Central (HTML)
PubMed (HTML)